Article Text

Download PDFPDF
Update in the molecular classification of endometrial carcinoma
  1. Alicia Léon-Castillo
  1. Department of Pathology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands
  1. Correspondence to Dr Alicia Léon-Castillo, Department of Pathology, Antoni van Leeuwenhoek, Amsterdam 1066CX, Netherlands; a.Leon{at}


The pathological classification of endometrial carcinomas, one of the cornerstones in patient clinical management, has traditionally been based on morphologic features. However, this classification system does not fully reflect the biological diversity of endometrial carcinomas and has limited reproducibility. In the last decade, several studies have reported the strong prognostic value of the molecular endometrial carcinoma subgroups and, more recently, its potential to inform adjuvant treatment decisions. This has in turn resulted in a transition from a purely morphological classification towards an integrated histological and molecular system in the latest World Health Organization (WHO) classification of tumors of female reproductive organs. The new European treatment guidelines combine the molecular subgroups with traditional clinicopathological features in order to guide treatment decision-making. Accurate molecular subgroup assignment is therefore essential for adequate patient management. This review aims to address caveats and evolution of molecular techniques relevant in the implementation of the molecular endometrial carcinoma classification, as well as challenges in the integration of the molecular subgroups with traditional clinicopathological features.

  • Uterine Cancer
  • Lynch Syndrome II
  • Pathology
  • Radiotherapy
  • Endometrial Neoplasms

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors AL-C conceived the idea and wrote the manuscript.

  • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests AL-C reports personal fees from Astra Zeneca and Diaceutics.

  • Provenance and peer review Commissioned; internally peer reviewed.